Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifteenth stock that takes place on our list is 4D Molecular Therapeutics, Inc.

TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target. Positive considerations for FDMT and the group in 2026 included the biotech industry’s solid fundamentals, the undervaluation of several companies, anticipated tailwinds from mergers and acquisitions, and a decreased emphasis on medicine prices.

Separately, on January 7, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) provided a 2026 corporate update. The 4FRONT Phase 3 investigations of 4D-150 in Wet AMD involved 480 patients in each phase; 381 participants have already been randomized for 4FRONT-1, and global enrollment for 4FRONT-2 is anticipated to be completed by H2 2026. A global Phase 3 trial for diabetic macular edema is scheduled for Q3, and 2-year SPECTRA Phase 1/2 results are anticipated in H2 2026. The second half of the year is also expected to see updates on the Phase 2 4D-710 program for cystic fibrosis.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical‑stage biotechnology company that develops targeted gene therapies using its proprietary Therapeutic Vector Evolution platform. It engineers customized AAV vectors to treat serious diseases like retinal disorders, cystic fibrosis, and cardiomyopathy, with multiple clinical and preclinical candidates advancing toward potential transformative treatments.

While we acknowledge the potential of FDMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.